![Foto de Manuel](/img/nophoto.png)
Manuel
Barreiro de Acosta
Manuel Barreiro de Acosta-rekin lankidetzan egindako argitalpenak (9)
2024
-
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Therapeutic Advances in Gastroenterology, Vol. 17
-
Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study
International Journal of Colorectal Disease, Vol. 39, Núm. 1
2023
-
Subclinical bowel inflammation increases healthcare resources utilization and steroid use before diagnosis of inflammatory bowel disease
United European Gastroenterology Journal, Vol. 11, Núm. 1, pp. 9-18
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study
Journal of Crohn's & colitis, Vol. 16, Núm. 9, pp. 1428-1435
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu
Journal of Clinical Medicine, Vol. 10, Núm. 19
2020
-
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
Clinical and translational gastroenterology, Vol. 11, Núm. 8, pp. e00218
2019
-
Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU
Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428